Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | CACNA1H | O95180 | 12/20 | 0.74 |
| ▸ | CACNA1C | Q13936 | 10/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | THPO | P40225 | 2/20 | 0.71 |
| ▸ | MTOR | P42345 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7449450 | 1.00 | CYP3A4 (1.00) | CYP3A4CACNA1HCACNA1CCYP2D6MAPT | |
| SCHEMBL22761579 | 1.00 | CYP3A4 (1.00) | CYP3A4CACNA1HCACNA1CCYP2D6MAPT | |
| SCHEMBL7273270 | 0.98 | CYP3A4 (0.95) | CYP3A4CACNA1HCACNA1CCYP2D6MAPT | |
| SCHEMBL7266333 | 0.97 | CYP3A4 (0.94) | CYP3A4CACNA1HCACNA1CCYP2D6MAPT | |
| SCHEMBL7267079 | 0.97 | CYP3A4 (0.94) | CYP3A4CACNA1HCACNA1CCYP2D6MAPT | |
| SCHEMBL7266465 | 0.97 | CYP3A4 (0.94) | CYP3A4CACNA1HCACNA1CCYP2D6MAPT | |
| Hydrochloric Acid SCHEMBL10539326 | 0.96 | CYP3A4 (0.92) | CYP3A4CACNA1HCACNA1CCYP2D6MAPT | |
| Hydrochloric Acid SCHEMBL7266400 | 0.96 | CYP3A4 (0.92) | CYP3A4CACNA1HCACNA1CCYP2D6MAPT | |
| Oxalic Acid SCHEMBL8353249 | 0.95 | CYP3A4 (0.90) | CYP3A4CACNA1HCACNA1CCYP2D6MAPT | |
| SCHEMBL10542576 | 0.90 | CYP3A4 (0.82) | CYP3A4CACNA1HCACNA1CCYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130750-B2 | Calcium channel inhibitors | CAVION, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11130750-B2 | Calcium channel inhibitors | CAVION, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200385367-A1 | CALCIUM CHANNEL INHIBITORS | CAVION, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200385367-A1 | CALCIUM CHANNEL INHIBITORS | CAVION, INC. | 2020-12-10 | — | — | US | disclosed |
| WO-1998049149-A1 | PREPARATION OF MIBEFRADIL I | F. HOFFMANN-LA ROCHE AG (CH) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998049147-A1 | PREPARATION OF MIBEFRADIL III | F. HOFFMANN-LA ROCHE AG (CH) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998049148-A1 | PREPARATION OF MIBEFRADIL II | F. HOFFMANN-LA ROCHE AG (CH) | 1998-11-05 | — | — | WO | disclosed |
| EP-0268148-B1 | TETRAHYDRONAPHTHALENE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | F. HOFFMANN-LA ROCHE AG (CH) | 1991-12-11 | — | — | EP | disclosed |
| US-4808605-A | Tetrahydronaphthalene derivatives as calcium antagonists | HOFFMANN-LA ROCHE INC. (US) | 1989-02-28 | — | — | US | disclosed |
| EP-0268148-A1 | Tetrahydronaphthalene derivatives and medicaments containing them | F. HOFFMANN-LA ROCHE AG (CH) | 1988-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130750-B2 | Calcium channel inhibitors | CACNA1F, ORAI1, CACNA1E | CYP3A4 2305/4885CACNA1H 12/4885CACNA1C 10/4885 |
| US-20200385367-A1 | CALCIUM CHANNEL INHIBITORS | CACNA1F, ORAI1, CACNA1E | CYP3A4 2305/4885CACNA1H 12/4885CACNA1C 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.